Get the Daily Brief
Latest Biotech News
Novartis to buy Pikavation for up to $3bn: adds mutant‑selective PI3Kα candidate
Novartis announced deals to acquire Pikavation Therapeutics and related PI3Kα programs in transactions worth up to $3 billion, including $2 billion upfront for SNV4818. The company says SNV4818 is...
Pfizer, Valneva post mixed Phase III results: >70% efficacy but trial missed primary bar
Pfizer and Valneva reported Phase III results for their Lyme disease vaccine showing roughly 70%+ efficacy but failing to meet a pre‑specified statistical threshold because fewer-than‑expected...
Apogee data show long‑acting eczema drug sustains relief: less frequent dosing works
Apogee Therapeutics released Phase II maintenance data showing its IL‑13 antibody zumilokibart maintained high response rates with dosing every three or six months. The company reported durable...
Oryon unveils autologous neuron replacement therapy – presents Phase Ib/IIa data
Oryon Cell Therapies emerged from stealth to present early clinical data for an autologous neuron replacement program in Parkinson’s disease and announced fresh funding and leadership moves. The...
Kali inks $1.2bn Sanofi deal – trispecific KT‑501 licensed for autoimmune indications
Kali Therapeutics signed a global licensing agreement with Sanofi for its trispecific T‑cell engager KT‑501 in a deal that could reach $1.2 billion. Sanofi will provide roughly $180 million in...
Rivia raises $15m – agentic AI to cut trial data review timelines
Swiss startup Rivia closed a $15 million Series A to scale an “agentic” AI platform aimed at real‑time unification and management of clinical trial data and to expand into U.S. biotech hubs,...
Study finds metformin activates genetic 'locks' – delays HIV rebound after ART
Researchers at Gladstone Institutes reported that two cellular genes act as 'locks' keeping HIV reservoirs dormant and that metformin can activate one of those mechanisms, delaying viral rebound...
Bionano reports revenue dip but narrows loss; CMS hikes OGM reimbursement
Bionano Genomics reported a 3% year‑over‑year decline in Q4 revenue and narrowed its net loss substantially versus the prior year, citing steady R&D and reduced SG&A. The company sold fewer flow...
Crossbow closes $77m Series B to advance T‑bolt T‑cell engagers
Crossbow Therapeutics raised $77 million in a Series B round to advance its T‑Bolt platform and first‑in‑class T‑cell engager CBX‑250 into and through Phase I studies for myeloid malignancies. CEO...
IDT enters IVD market with Archer FusionPlex‑HT Dx and VariantPlex‑HT Dx assays
Danaher subsidiary Integrated DNA Technologies launched two in vitro diagnostic (IVD) NGS library‑preparation assays—Archer FusionPlex‑HT Dx and Archer VariantPlex‑HT Dx—marking a strategic move...
Novartis to buy Pikavation—up to $3B for mutant‑selective PI3Kα
Novartis announced acquisitions and license moves to bolster its PI3Kα oncology portfolio, agreeing to acquire Pikavation and to pay up to $3 billion and separately committing billions to...
Pfizer, Valneva: Lyme vaccine cuts ~73% of cases — misses key statistical hurdle
Pfizer and Valneva reported Phase 3 results showing their Lyme disease vaccine reduced infections by roughly 70–73% but failed to meet the trial’s pre‑specified statistical criterion. The partners...
Apogee’s long‑acting eczema drug: 3‑ and 6‑month dosing sustains response
Apogee Therapeutics released mid‑stage maintenance data showing its anti‑IL‑13 antibody, zumilokibart (APG‑777), produced durable clinical responses with three‑ and six‑month maintenance dosing in...
Kali inks $1.2B Sanofi pact — trispecific T‑cell engager licensed
Kali Therapeutics licensed its lead trispecific T‑cell engager KT‑501 to Sanofi in a deal worth up to $1.2 billion, including substantial near‑term payments. Sanofi described the arrangement as a...
Crossbow raises $77M — funds CBX‑250 first‑in‑human push
Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and lead candidate CBX‑250, a T‑cell engager targeting intracellular tumor antigens via HLA‑presented peptides....
Rivia raises $15M — agentic AI to cut trial review times
Swiss startup Rivia closed a $15 million Series A to scale an agentic AI platform intended to unify and structure clinical trial data in real time and surface prioritized data‑quality issues. CEO...
China’s trial reforms: implied approval accelerates IND starts
Analysts and US policymakers highlighted sweeping changes in China’s clinical‑trial rules that have dramatically shortened timelines for starting human studies, including a 2018 'implied approval'...
Insmed’s Arikayce wins late‑stage trial — eyes front‑line lung use
Insmed reported positive Phase 3 data showing Arikayce added to standard therapy improved respiratory symptoms and culture conversion rates in patients with newly diagnosed Mycobacterium avium...
Laigo extends seed to €17M — protein‑degradation tech moves toward clinic
Laigo Bio extended its seed round to €17 million as it advances a novel E3 ligase‑based targeted protein degradation platform toward clinical translation. The additional capital will support...
Tessera wins Gates grant — genetic strategies for scalable HIV cure
Tessera Therapeutics received a grant from the Bill & Melinda Gates Foundation to support early‑stage research exploring genetic approaches aimed at a scalable HIV cure. Tessera said funding will...